Ubamatamab
Based on 1 Customer Validation
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity.
For research use only. We do not sell to patients.
- Purity : ≥99.0%
- CAS No.: 2305629-50-7
- Molecular Weight:146.081 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD3E & MUC16
In Vitro
Ubamatamab (REGN4018; 0.1 pM-10 nM; 48 hours) induces human T cells and cynomolgus T cells to kill OVCAR-3 cells (EC50, 13.6 pM and 30.6 pM, respectively)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:OVCAR-3 cells
-
Concentration:0.1 pM-10 nM
-
Incubation Time:48 hours
-
Result:Induced human T cells and cynomolgus T cells to kill OVCAR-3 cells.
In Vivo
Ubamatamab (REGN4018; 0.01-1 mg/kg; i.p; once a week; total of five doses) shows minimal and transient increases in serum cytokines and C-reactive protein, with no overt toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD SCID gamma (NSG) mice injected with OVCAR-3/Luc cells[1]
-
Dosage:0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg
-
Administration:i.p; on days 6, 10, 13, 16, and 21
-
Result:Significantly reduced tumor burden, and did not result in any changes in weight.
-
Animal Model:Cynomolgus monkeys
-
Dosage:0.01, 0.1, or 1 mg/kg
-
Administration:i.p; once a week; total of five doses
-
Result:Showed minimal and transient increases in serum cytokines and C-reactive protein.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CA125 Protein, Human can bind Ubamatamab. The EC50 for this effect is 8.59 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Ubamatamab (HY-P99539). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa Isotype Control (HY-P99003, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2305629-50-7
-
Appearance Liquid
-
Molecular Weight 146.081 kDa
-
Color Colorless to light yellow
-
SMILES
[Ubamatamab]
-
Synonyms
REGN4018
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)